August 14, 2024 01:01 PM EDTUpdated 01:34 PM

Sanofi backs AnaptysBio’s $100M offering, helping catapult the biotech’s stock

Max Bayer

Pharma Reporter

AnaptysBio is riding Wall Street momentum, reporting its highest share price in almost five years after a $100 million offering that brought Sanofi aboard. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi backs AnaptysBio’s $100M offering, helping catapult the biotech’s stock

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Exclusive: J&J folds cardiovascular and metabolic drug unit

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

US government renews threats over J&J's proposed 340B rebate model

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Sanofi backs Anap­tys­Bio’s $100M of­fer­ing, help­ing cat­a­pult the biotech’s stock

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Sanofi backs AnaptysBio’s $100M offering, helping catapult the biotech’s stock